StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.35+0.03 (+2.27%)

Close on Nov 16, 2026Market cap $1.37MP/E –Yield –

Transcode Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Transcode Therapeutics's total assets was $151.01M at Jun 30, 2026. For fiscal 2025 it was $162.40M, up 2126.3% from the year before. The highest annual figure on record is $162.40M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$162.40M+2126.3%
FY2024Dec 31, 2024$7.29M+41.1%
FY2023Dec 31, 2023$5.17M-31.9%
FY2022Dec 31, 2022$7.59M-66.9%
FY2021Dec 31, 2021$22.94M+2073.5%
FY2020Dec 31, 2020$1.06M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$151.01M+1726.8%
Q1 FY2026Mar 31, 2026$157.16M+1091.2%
Q4 FY2025Dec 31, 2025$162.40M+2126.3%
Q3 FY2025Sep 30, 2025$5.23M+32.8%
Q2 FY2025Jun 30, 2025$8.27M+71.3%
Q1 FY2025Mar 31, 2025$13.19M+81.0%
Q4 FY2024Dec 31, 2024$7.29M+41.1%
Q3 FY2024Sep 30, 2024$3.94M-61.5%
Q2 FY2024Jun 30, 2024$4.82M-18.0%
Q1 FY2024Mar 31, 2024$7.29M+30.4%
Q4 FY2023Dec 31, 2023$5.17M-31.9%
Q3 FY2023Sep 30, 2023$10.23M-14.9%
Q2 FY2023Jun 30, 2023$5.88M-58.5%
Q1 FY2023Mar 31, 2023$5.59M-70.3%
Q4 FY2022Dec 31, 2022$7.59M-66.9%
Q3 FY2022Sep 30, 2022$12.02M-52.6%
Q2 FY2022Jun 30, 2022$14.16M+829.9%
Q1 FY2022Mar 31, 2022$18.85M+1686.1%
Q4 FY2021Dec 31, 2021$22.94M–
Q3 FY2021Sep 30, 2021$25.36M–
Q2 FY2021Jun 30, 2021$1.52M–
Q4 FY2020Dec 31, 2020$1.06M–

More Transcode Therapeutics figures

See a number that looks wrong?